Anti-obesity drugs fatten Novo Nordisk profits
Danish drugmaker Novo Nordisk reported Thursday a sharp rise in third quarter sales and profits driven by the success of its anti-diabetes and anti-obesity treatments Ozempic and Wegovy.
Nov 2, 2023
0
0